Metfogamma 500

Metformin Hydrochloride, the active ingredient in Metfogamma 500, is a biguanide presented as a 500 mg tablet for oral use. It is used to lower blood glucose levels in patients with type 2 diabetes mellitus and related glucose‑handling disorders.

GNH USA supplies Metfogamma 500 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metfogamma (metformin hydrochloride) is employed in the management of disorders that involve insulin resistance and elevated blood glucose.

- Type 2 diabetes mellitus: improves glycaemic control by reducing hepatic glucose output and enhancing peripheral insulin sensitivity. - Prediabetes (impaired fasting glucose): helps delay progression to overt type 2 diabetes. - Polycystic ovary syndrome: reduces insulin resistance and may improve menstrual regularity.

Metfogamma may cause a range of adverse reactions, most of which are related to the gastrointestinal tract, while rare events can be serious.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: frequent loose stools. - Abdominal discomfort: cramping or pain. - Metallic taste: transient alteration of taste perception. - Weight loss: modest reduction in body weight. - Loss of appetite: decreased desire to eat.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic disturbance. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatic dysfunction: elevated liver enzymes. - Pancreatitis: inflammation of the pancreas. - Anemia: reduction in red blood cell count. - Hypoglycaemia: low blood sugar, usually when combined with other glucose‑lowering agents.

When prescribing Metfogamma, clinicians should consider several safety measures to minimise risk.

- Renal function monitoring: assess creatinine clearance before initiation and periodically thereafter. - Hepatic function monitoring: evaluate liver enzymes at baseline and during therapy. - Contraindication in severe heart failure: avoid use in patients with unstable or acute heart failure. - Use with caution in the elderly: dose adjustments may be required due to reduced renal clearance. - Pregnancy and lactation: safety category unknown; weigh potential benefits against risks. - Store at room temperature: keep in the original container, protect from moisture and heat.

Metfogamma can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: increase risk of lactic acidosis; discontinue metformin before and after imaging. - Cimetidine: may raise metformin plasma concentrations. - Alcohol: potentiates risk of lactic acidosis. - Diuretics that impair renal function: can reduce metformin clearance. - Certain antiretrovirals (e.g., didanosine): may increase toxicity.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - ACE inhibitors or ARBs: monitor renal function and potassium levels. - NSAIDs: can affect renal perfusion, requiring dose review. - Sulfonylureas: increased risk of hypoglycaemia; adjust dose as needed. - Digoxin: monitor for signs of toxicity.